Prevalence and incidence of arrhythmias and sudden death in heart failure

Heart Failure Reviews

Volumn 7, Issue 3, 2002, Pages 229-242

  Cleland, John G F ^a   Chattopadhyay, Sudipta ^a   Khand, Aleem ^a   Houghton, Timothy ^a   Kaye, Gerald C ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Arrhythmia; Heart failure; Prevalence; Sudden death

Indexed keywords

AMIODARONE; AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CAPTOPRIL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; ENALAPRIL; HYDRALAZINE; IBOPAMINE; ISOSORBIDE MONONITRATE; LISINOPRIL; LOSARTAN; METOPROLOL; MILRINONE; PIPERANOMETOZINE; PLACEBO; PRAZOSIN; SPIRONOLACTONE; VALSARTAN;

BRADYCARDIA; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MEGADOSE; EPIDEMIOLOGICAL DATA; HEALTH SURVEY; HEART ARREST; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART RHYTHM; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; INCIDENCE; PREDICTION; PREVALENCE; PROGNOSIS; PROVOCATION; QT INTERVAL; REVIEW; SIGNAL AVERAGED ELECTROCARDIOGRAPHY; SINUS RHYTHM; STATISTICAL SIGNIFICANCE; SUDDEN DEATH; SYMPTOM; SYNCOPE;

ADULT; AGED; ATRIAL FIBRILLATION; COMPUTER GRAPHICS; DEATH, SUDDEN, CARDIAC; ELECTROCARDIOGRAPHY; GREAT BRITAIN; HEART FAILURE, CONGESTIVE; HUMANS; INCIDENCE; MIDDLE AGED; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; VENTRICULAR FIBRILLATION;

EID: 0036660157     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020024122726     Document Type: Review

References (120)

1. Khand A, Rankin AC, Kaye GC, Cleland JGF. Systematic review of the management of atrial fibrillation in patients with heart failure. Eur Heart J 2000;21:614-632.
2. Cleland JGF, Thackray S, Goodge L, Kaye GC, Cooklin M. Outcome studies with device therapy in patients with heart failure. J Cardiovasc Electrophysiol 2002;13:(1 Suppl):S73-91.
3. Teerlink JR, Jalaluddin M, Anderson S, et al. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. Circulation 2000;101:40-46.
4. Cohn JN, Johnson GR, Shabetai R, et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. Circulation. 1993;87:V15-V16.
5. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-883.
6. Anderson JL, Platia EV, Hallstrom A, et al. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction: A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). Circulation 1994;90:2843-2852.
7. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo - The Cardiac Arrhythmia Suppression Trial. New Engl J Med 1991;324:781-788.
8. Greenberg HM, Dwyer Jr EM, Hochman JS, Steinberg JS, Echt DS, Peters RW. Interaction of ischaemia and encainide/flecainide treatment: A proposed mechanism for the increased mortality in CAST I. Br Heart J 1995;74:631-635.
9. Cleland JGF. Screening for left ventricular dysfunction and chronic heart failure: Should it be done and, if so, how? Dis Manage Health Outcomes 1997;4:169-184.
10. Cleland J, Swedberg K., Cohen Solal A, et al. The EuroHeart Failure Survey of the EUROHEART Survey Programme: A survey on the quality of care among patients with heart failure in Europe. Eur J Heart Fail 2000;2:123-132.
11. Cleland JGF, Swedberg K, Follath F, Widimsky J. The IMPROVEMENT of heart failure survey. International variations in the aetiology of heart failure managed in primary care. Eur J Heart Fail 2001;3:S72(Abstract).
12. Cleland JGF, Khand A, Clark AC. The heart failure epidemic: Exactly how big is it? Eur Heart J 2001;22:623-626.
13. Davies MK, Hobbs FDR, Davis RC, et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening Study: A population based study. The Lancet 2001;358:439-444.
14. Senges JC, Becker R, Schreiner KD, et al. Variability of Holter electrocardiographic findings in patients fulfilling the noninvasive MADIT criteria. Multicenter Automatic Defibrillator Implantation Trial. Pacing Clin Electrophysiol 2002;25:183-190.
15. Middlekauf HR, Stevenson WG, Warner-Stevenson L, Saxon LA. Syncope in advanced heart failure: High risk of sudden death regardless of origin of syncope. J Am Coll Cardiol 1993;21:110-116.
16. Fruhwald FM, Eber B, Schumacher M, et al. Syncope in dilated cardiomyopathy is a predictor of sudden cardiac death. Cardiology 1996;87:177-180.
17. Fonarow GC, Feliciano Z, Boyle NG, et al. Improved survival in patients with nonischemic advanced heart failure and syncope treated with an implantable cardioverter-defibrillator. Am J Cardiol 2000;85:981-985.
18. Cleland JGF, Thygesen K, Uretsky BF, et al. Cardiovascular critical event pathways for the progression of heart failure. A report from the ATLAS study. Eur Heart J 2001;22:1601-1612.
19. Cleland JGF, Massie BM, Packer M. Sudden death in heart failure: Vascular or electrical? Eur J Heart Fail 1999;1:41-45.
20. Wilkoff BL, Kuhlkamp V, Volosin K, et al. Critical analysis of dual-chamber implantable cardioverter-defibrillator arrhythmia detection. Circulation 2001;103:381.
21. Sticherling C, Schaumann A, Hohnloser SH. First worldwide clinical experience with a new dual chamber implantable cardioverter defibrillator. Advantages and complications. The Ventak AV II DR Investigators. Europace 1999;1:96-102.
22. Wood MA, Stambler BS, Greenway P, Ellenbogen K. Lessons learned from data logging in a multicenter clinical trial using a late-generation implantable cardioverter-defibrillator. The Guardian ATP 4210 Multicenter Investigations Group. J Am Coll Cardiol 1994;24:1692-1699.
23. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J 2000;21(24):2071-2078.
24. Bansch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy. Circulation 2002;105:1453.
25. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;333:2001-2007.
26. Kjekshus J. Arrhythmias and mortality in congestive heart failure. Am J Cardiol 1990;65:42 I-48 I
27. Hallstrom A, Pratt CM, Greene L, et al. Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: Analysis of the cardiac arrhythmia suppression trial. J Am Coll Cardiol 1995;25:1250-1257.
28. Luu M, Stevenson WG, Stevenson LW, Baron K, Walden J. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation 1989;80:1675-1680.
29. Mosterd A, Hoes AW, Bruijne de MC, et al. Prevalence of heart failure and left ventricular dysfunction in the general population. The Rotterdam Study. Eur Heart J 1999;20:447-455.
30. Mosterd A, Cost B, Hoes AW, et al. The prognosis of heart failure in the general population: The Rotterdam Study. Eur Heart J 2001;22:1318-1327.
31. Khand AU, Gemmell I, Rankin AC, Cleland JGF. Clinical events leading to the progression of heart failure: Insights from a national database of hospital discharges. Eur Heart J 2001;22:153-164.
32. Yusuf S, et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. New Engl J Med 1992;327:685-691.
33. Yusuf S, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New Engl J Med 1991;325:293-302.
34. Cohn JN, Tognoni G. For the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675.
35. Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farrell L, Cohn JN. The influence of atrial fibrillation on prognosis in mild to moderate heart failure: The V-HeFT studies. Circulation 1993;87:VI102-VI110.
36. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative Study. New Engl J Med 1986;314:1547-1552.
37. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. New Engl J Med 1991;325:303-310.
38. Cohn JN, Tognoni G, Glazer RD, Spormann D. Baseline demographics of the valsartan heart failure trial. Eur J Heart Failure 2000;2:439-446.
39. Fletcher RD, Cintron GB, Johnson G, Orndorff J, Carson P, Cohn JN. Enalapril decreases prevalence of ventricular tachycardia in patients with chronic congestive heart failure. Circulation 1993;87:VI49-VI55.
40. Goldman S, Johnson G, Cohn JN, Cintron G, Smith R, Francis G. Mechanism of death in heart failure: The Vasodilator-Heart Failure Trials. Circulation 1993;87:VI24-VI31.
41. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. New Engl J Med 1991;325:1468-1475.
42. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. New Engl J Med 1996;334:1349-1355.
43. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. New Engl J Med 1996;335:1107-1114.
44. Packer M, Poole Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312-2318.
45. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. New Engl J Med 2001;344:1651-1658.
46. O'Connor CM, Belkin RN, Carson PE, et al. Effect of amlodipine on mode of death in severe chronic heart failure: the PRAISE trial. Circulation 1995;92 (Supp. I):1-143 (Abstract).
47. Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med 1998;339:1810-1816.
48. Pitt B, Poole-Wilson PA, Sega R, et al. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: Rationale, design and baseline characteristics of patients in the Losartan Heart Failure Survival Study - ELITE II. J Card Fail 1999;5:146-154.
49. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717.
50. Pitt B, Poole Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-1587.
51. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. New Engl J Med 1997;336:525-533.
52. CIBIS-II Investigators and Commitee. The Cardiac insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999;353:9-13.
53. Singh SN, Fisher SG, Carson PE, Fletcher RD, and the Department of Veterans Affairs CHF STAT Investigators. Prevalence and significance of nonsustained ventricular tachycardia in patients with premature ventricular contractions and heart failure with vasodilator therapy. J Am Coll Cardiol 1998;32:942-947.
54. Hampton JR, Van Veldhuisen D, Kleber FX, et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Lancet 1997;349:971-977.
55. Doval HC, Nul DR, Grancelli HI, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994;344:493-498.
56. Swedberg K, Idanpaan Heikkila U, Remes J, for the CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New Engl J Med. 1987;316:1429-1435.
57. Doval HC, Nul DR, Grancelli HO, et al. Nonsustained ventricular tachycardia in severe heart failure. Circulation 1996;94:3198-3203.
58. Pedersen OD, Bagger H, Keller N, et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: A Danish investigations of arrhythmia and mortality ON dofetilide (DIAMOND) substudy. Circulation 2001;104:292-296.
59. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 1999;341:857-865.
60. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. New Engl J Med 2001;344:1659-1667.
61. Cleland JGF, Armstrong P, Horowitz JD, et al. Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study. Eur J Heart Failure 1999;1:73-79.
62. Andersson B, Caidahl K, Waagstein F. An echocardiographic evaluation of patients with idiopathic heart failure. Chest 1995;107(3):680-689.
63. McDermott MM, Feinglass J, Sy J, Gheorghiade M. Hospitalized congestive heart failure patients with preserved versus abnormal left ventricular systolic function: Clinical characteristics and drug therapy. Am J Med 1995;99:629-635.
64. McAlister FA, Teo KK, Taher M, et al. Insights into the contemporary epidemiology and outpatient management of congestive heart failure. Am Heart J 1999;138:87-94.
65. Crijns HJGM, Tjeersdsma PJ, de Kam P-J, et al. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J 2001;21:1238-1245.
66. Pozzoli M, Cioffi G, Traversi E, Pinna GD, Cobelli F, Tavazzi L. Predictors of primary atrial fibrillation and concomitant clinical and haemodynamic changes in patients with chronic heart failure: A prospective study in 344 patients with baseline sinus rhythm. JACC 1998;32:197-204.
67. Pratt CM, Gardner M, Pepine C, et al. Lack of long-term ventricular arrhythmia reduction by enalapril in heart failure. Am J Cardiol 1995;75:1244-1249.
68. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. New Engl J Med 1995;333:77-82.
69. Gall NP, Zaman A, O'Nunain S, Fox KA, Flapan A, Nolan J. Implementation of the NICE guidelines for the primary prevention of mortality from ventricular tachyarrhythmias: Implications for UK electrophysiology centres; activity modelling from the UK-HEART study. Heart 2001;86:219-220.
70. Nolan J, Batin PD, Andrews R, et al. Prospective study of heart rate variability and mortality in chronic heart failure: Results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation 1998;98:1510-1516
71. Cleland JGF, Dargie HJ, Ford I. Mortality in heart failure: Clinical variables of prognostic value. Br Heart J 1987;58:572-582.
72. Tofler GH, Gebara OC, Mittleman MA, et al. Morning peak in ventricular tachyarrhythmias detected by time of implantable cardioverter/defibrillator therapy. Circulation 1995;92:1203-1208.
73. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, et al. Effects of controlled-release metoprolol on total mortality, hospitalization, and well-being in patients with heart failure: The metoprolol CR-XL randomized intervention trial in congestive heart failure (MERIT-HF). JAMA 2000;283:1295-1302.
74. Ho KKL, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in the Framingham heart study subjects. Circulation 1993;88:107-115.
75. Croft JB, Giles WH, Pollard RA, Keenan NL, Casper ML, Anda RF. Heart failure survival among older adults in the United States: A poor prognosis for an emerging epidemic in the Medicare population. Arch Intern Med 1999;159:505-510.
76. Cleland JGF, Erhardt L, Murray G, Hall AS, Ball SG. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. Eur Heart J 1997;18:41-51.
77. Cowburn PJ, Cleland JGF, Coats AJS, Komajda M. Risk stratification in chronic heart failure. Eur Heart J 1998;19:696-710.
78. Komajda M, Jais JP, Reeves B, et al. Factors predicting mortality in idiopathic dilated cardiomyopathy. Eur Heart J 1990;11:824-831.
79. Warner-Stevenson L, Fowler MB, Schroeder JS, Stevenson WG, Dracup KA, Fond V. Poor survival of patients with idiopathic cardiomyopathy considered too well for transplantation. Am J Med 1987;83;871-876.
80. Stevenson WG, Middlekauf HR, Stevenson LW, et al. Significance of aborted cardiac arrest and sustained ventricular tachycardia in patients referred for treatment of advanced heart failure. Am Heart J 1992;124:123-130.
81. De Maria R, Gavazzi A, Caroli A, et al. Ventricular arrhythmias in dilated cardiomyopathy as an independent prognostic hallmark. Am J Cardiol 1992;69:1451-1457.
82. Olshausen KV, Steinen U, Math D, et al. Long term prognostic significance of ventricular arrhythmias in idiopathic dilated cardiomyopathy. Am J Cardiol 1988;61:146-151.
83. Reese DB, Silverman ME, Gold MR, Gottlieb SS. Prognostic importance of the length of ventricular tachycardia in patients with nonischaemic congestive heart failure. Am Heart J 1995;130:489-493.
84. Unverferth DV, Magorien RD, Moeschberger ML, et al. Factors influencing the one year mortality of dilated cardiomyopathy. Am J Cardiol 1984;54:147-152.
85. CIBIS Investigations and Committee. A randomized trial of B-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-1773.
86. Wilson JR, Schwartz JS, Sutton MS, et al. Prognosis in severe heart failure: Relation to hemodynamic measurements and ventricular ectopic activity. JACC 1983;2:403-410.
87. Soifer S, Nul DR, Grancelli HO, et al. Different predictors in sudden or progressive heart failure death in severe heart failure. JACC 1997;29:247A(Abstract).
88. Gomes JA, Mehta D, Ip J, et al. Predictors of long-term survival in patients with malignant ventricular arrhythmias. Am J Cardiol 1997;79:1054-1060.
89. Massie BM, Podrid PJ, Hendrix GH, et al. Does asymptomatic worsening of arrhythmia predict sudden death in heart failure? Evidence for clinically significant proarrhythmia during milrinone therapy (Abstract). JACC 1992;19:78A.
90. Brembilla-Perrot B, Terrier de la Chasse A, Jacquemin L, Beurrier D, Houplon P. The signal-averaged electrocardiogram is of limited value in patients with bundle branch block and dilated cardiomyopathy in predicting inducible ventricular tachycardia or death. Am J Cardiol 1997;79:154-159.
91. Gonska BD, Bethge KP, Figulla HR, Kreuzer H. Occurence and clinical significance of endocardial late potentials and fractionations in idiopathic dilated cardiomyopathy. Br Heart J 1988;59:39-46.
92. Mancini DM, Wong KL, Simson MB. Prognostic value of an abnormal signal-averaged electrocardiogram in patients with nonischemic congestive cardiomyopathy. Circulation 1993;87:1083-1092.
93. Ohnishi Y, Inoue T, Fukuzaki H. Value of the signal-averaged electrocardiogram as a predictor of sudden death in myocardial infarction and dilated cardiomyopathy. Jpn Circ 1990;54:127-136.
94. Poll DS, Marchlinski FE, Falcone RA, Josephson ME, Simson MB. Abnormal signal-averaged electrocardiograms in patients with nonischemic congestive cardiomyopathy: Relationship to sustained ventricular tachyarrhythmias. Circulation 1985;72:1308-1313.
95. Silverman ME, Pressel MD, Brackett JC, et al. Prognostic value of the signal-averaged electrocardiogram and a prolonged QRS in ischemic and nonischemic cardiomyopathy. Am J Cardiol 1995;75:460-464.
96. Turrito G, Ahuja RK, Caref EB, El-Sherif N. Risk stratification for arrhythmic events in patients with nonischaemic dilated cardiomyopathy and nonsustained ventricular tachycardia: Role of programmed ventricular stimulation and the signal averaged electrocardiogram. JACC 1994;24:1523-1528.
97. Keeling PJ, Kulakowski P, Yi G, Slade AKB, Bent SE, McKenna WJ. Usefulness of signal-averaged electrocardiogram in idiopathic dilated cardiomyopathy for identifying patients with ventricular arrhythmias. Am J Cardiol 1993;72:78-84.
98. Denereaz D, Zimmerman M, Adamec R. Significance of ventricular late potentials in non-ischaemic dilated cardiomyopathy. Eur Heart J 1992;13:895-901.
99. Yi G, Keeling PJ, Goldman JH, Jian H, Poloniecki J, McKenna WJ. Prognostic significance of spectral turbulence analysis of the signal-averaged electrocardiogram in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 1995;75:494-497.
100. Kuchar DL, Thorburn CW, Sammel NL. Prediction of serious arrhythmic events after myocardial infarction: Signal-averaged electrocardiogram, holter monitoring and radio-nuclide ventriculography. J Am Coll Cardiol 1987;9:531-538.
101. Bigger JTJ, Whang W, Rottman JN, et al. Mechanisms of death in the CABG Patch Trial. A randomized trial of implantable cardiac defibrillator prophylaxis in patients at high risk of death after coronary bypass graft surgery. Circulation 1999;99:1416-1421.
102. Bigger JT, for the Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. New Engl J Med 1997;337:1569-1575.
103. Galinier M, Albenque JP, Afchar, et al. Prognostic value of late potentials in patients with congestive heart failure. Eur Heart J 1996;17:264-271.
104. Middlekauf HR, Stevenson WG, Woo MA, et al. Comparison of frequency of late potentials in idiopathic dilated cardiomyopathy and ischemic cardiomyopathy with advanced congestive heart failure and their usefulness in predicting sudden death. Am J Cardiol 1990;66:1113-1117.
105. Barr CS, Naas A, Freeman M, Lang CC, Struthers AD. QT dispersion and sudden unexpected death in chronic heart failure. Lancet 1994;343:327-329.
106. Pinsky DJ, Sciacca RR, Steinberg JS. QT Dispersion as a marker of risk in patients awaiting heart transplantation. JACC 1997;29:1576-1584.
107. Brendorp B, et al. Effect of dofetilide on QT dispersion and the prognostic implications of changes in QT dispersion for patients with congestive heart failure. Eur Heart J Failure 2002;4:201-206.
108. Zareba W, et al. Dispersion of ventricular repolarisation and arrhythmic death in coronary artery disease. Am J Cardiol 2002;74:550-553.
109. Fei L, Goldman JH, Prasad K, et al. QT dispersion and RR variations on 12-lead ECGs in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy. Eur Heart J 1996;17:258-263.
110. Grimm W, Steder U, Menz V, et al. QT dispersion and arrhythmic events in idiopathic dilated cardiomyopathy. Am J Cardiol 1996;78:458-461.
111. Brooksby P, Batin PD, Nolan J, et al. The relationship between QT intervals and mortality in ambulant patients with chronic heart failure. The United Kingdom heart failure evaluation and assessment of risk trial (UK-HEART). Eur Heart J 1999;20:1290-1292.
112. Fu GS, Meissner A, Simon R. Repolarization dispersion and sudden cardiac death in patients with impaired left ventricular function. Eur Heart J 1997;18:281-289.
113. Meinertz T, Treese N, Kasper W, et al. Determinants of prognosis in idiopathic dilated cardiomyopathy as determined by programmed electrical stimulation. Am J Cardiol 1985;56:337-341.
114. Milner PG, DiMarco JP, Lerman BB. Electrophysiological evaluation of sustained ventricular tachyarrhythmias in idiopathic dilated cardiomyopathy. PACE 1988;11:562-568.
115. Stevenson WG, Stevenson LW, Weiss J, Tillisch JH. Inducible ventricular arrhythmias and sudden death during vasodilator therapy of severe heart failure. Am Heart J 1988;116:1447-1454.
116. Chen X, Shenasa M, Borggrefe M, et al. Role of programmed ventricular stimulation in patients with idiopathic dilated cardiomyopathy and documented sustained ventricular tachyarrhythmias: Inducibility and prognosis value in 102 patients. Eur Heart J 1994;15:76-82.
117. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999;341:1882-1890.
118. Buxton AE, Lee KL, DiCarlo L, et al. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter unsustained tachycardia trial investigators. N Engl J Med 2000;342:1937-1945.
119. Sager PT, Choudhary R, Rahimtoola SH, Bhandari AK. The long-term prognosis of patients with out-of-hospital cardiac arrest but no inducible ventricular tachycardia. Am Heart J 1990;120:1334-1342.
120. Lindsay BD, Osborn JL, Schechtman KB, et al. Prospective detection of vulnerability to sustained ventricular tachycardia in patients awaiting cardiac transplantation. Am J Cardiol 1992;69:619-624.